This clinical trial determines whether a high-intensity interval training exercise program improves brain health as well as cardiovascular (heart) function among women with stage I-III breast cancer undergoing chemotherapy. There is some evidence that there can be cognitive changes after chemotherapy among some patients with breast cancer. The information learned by doing this research study may help determine whether participating in a specific exercise program can improve brain and heart health.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04724499.
Locations matching your search criteria
United States
Massachusetts
Boston
Dana-Farber Cancer InstituteStatus: Active
Contact: Christina Dieli-Conwright
Phone: 617-582-8321
Brigham and Women's HospitalStatus: Active
Contact: Christina Dieli-Conwright
Phone: 617-582-8321
PRIMARY OBJECTIVES:
I. To determine the effects of a 16-week high-intensity interval training (HIIT) exercise intervention on executive functioning and memory in 50 breast cancer patients undergoing chemotherapy.
II. To determine the effects of a 16-week exercise intervention on resting state connectivity and structural diffusion tensor imaging (DTI) connectivity in 50 breast cancer patients undergoing chemotherapy.
SECONDARY OBJECTIVE:
I. To determine the effects of a 16-week exercise intervention on cardiorespiratory fitness in 50 breast cancer patients undergoing chemotherapy.
TERTIARY OBJECTIVE:
I. To determine the effects of a 16-week exercise intervention on body composition, physical fitness, and psychosocial health.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (HIIT): Patients undergo supervised exercise using a stationary bike 3 days per week for 16 weeks.
GROUP II (ATTENTION CONTROL): Patients perform stretching exercises 3 days per week for 16 weeks.
In both groups, patients also undergo magnetic resonance imaging (MRI) over 120 minutes at weeks 1, 18 and 34, and cognitive and cardiopulmonary assessments over 60 and 10 minutes respectively at weeks 1, 9, 18 and 34 and blood sample collection on study.
After completion of study treatment, patients in Group I are followed up for 4 months.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorChristina Dieli-Conwright